Beigene Nordics Is The Nordic Branch Of Beigenea Global Biotechnology Company Focused On Oncologythe Company Is Dedicated To Developing Innovative Cancer Treatments While Ensuring Patient Accessibility And Affordabilitywith A Team Of Over 10 000 Employees Worldwidebeigene Operates In More Than 40 Marketscollaborating Closely With Its Global Network To Advance Cancer Therapies The Nordic Team Plays A Vital Role In Clinical Researchconducting Over 40 Phase 3 Or Registration Enabling Trials Globallythey Provide Patient Support Resources To Help Individuals And Families Navigate The Challenges Of Cancer Diagnosis And Treatmentbeigene Nordics Is Committed To Serving Cancer Patientshaving Treated Over 1 3 Million Patients Globally With Its Medicinestheir Product Portfolio Includes Brukinsaa Zanubrutinib A Btk Inhibitor For Hematologic Malignanciesand Tevimbraa Tislelizumab A Pd 1 Inhibitor For Solid Tumors
